Market Research Reports and Industry Reports

MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the clean label. These issues will limit the initial uptake of Invokana to a small segment of diabetic patients - we think patients moving to triple OAD, on GLP-1 or Insulin (due to insufficient control from existing therapies, and escalating disease) are the broader target base of Invokana. Within this broader patient pool, ~40% patients with renal risks, >30% obese patients with co-morbid conditions and CV risks, and females at high UTI infection risk need to be restricted further this leaves a merely ~263k (or ~2.1% of total OAD patients) patients in the US for SGLT-2 inhibitors
Taking All Factors into Account, We arrive the Following Target Patient Base for Invokana (Table 4, 5- Invokana Market Model):.
We expect the market share to split between Invokana: Empagliflozin: Dapagliflozin by ~55:35:10 respectively as
Based on the available data comparision of Empagliflozin vs. Invokana, its efficacy looks better than Empagliflozin. While on safety front, based on PhIIb data empagliflozin reported less genital mycotic infections and equivalent UTI infection to Invokana when indirectly compared.
N/A

List Of Tables

N/A

List Of Figures

N/A

Bank of Tokyo-Mitsubishi.. Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Bank of Tokyo-Mitsubishi.. Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

Bank of Tokyo-Mitsubishi UFJ Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Bank of Tokyo-Mitsubishi UFJ Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

Mitsubishi Chemical Corporation - Strategy, SWOT and Corporate Finance Report

Mitsubishi Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT analysis, product and

USD 175View Report

Mitsubishi Tanabe Pharma Corporation - Strategy, SWOT and Corporate Finance Report

Mitsubishi Tanabe Pharma Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT analysis, product

USD 175View Report

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016Global Markets Directs, Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016, provides an overview of the Mitsubishi Tanabe Pharma

USD 1500View Report

Mitsubishi Tanabe Pharma Corporation (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) is a pharmaceutical company that identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Apr 2013
No. of Pages :9
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment